NewsEvents

Your Yourlocation: Home > The tiotropium bromide(136310-93-5) group and the salmeterol group did not show unexpected safety events in the study

The advantage of tiotropium bromide(136310-93-5) is as early as the first month of treatment and is always maintained during the one-year study period.

The safety analysis of the study also confirmed that the tiotropium bromide(136310-93-5) group and the salmeterol group did not show unexpected safety events in the study. Serious adverse events, leading to adverse events of treatment termination and the incidence of fatal adverse events were similar in both groups of patients.

"COPD acute exacerbation can occur even in the early stages of COPD, and may occur in the entire course of recurrence. COPD acute exacerbation can cause heavy personal, medical, social burden.To prevent acute exacerbation is the main goal of COPD treatment, but also COPD study patients ". The POET-COPD study is by far the largest study of the long-term effects of two long-acting bronchodilators on COPD acute exacerbations," said Professor Klaus Rabe of the Department of Pulmonary Diseases at the Leiden University Medical Center in the Netherlands. The findings will help guide clinical practice in COPD management and acute exacerbation."

"The acute exacerbation of COPD can induce cardiovascular disease, which has a serious impact on the quality of life of the patient, the disease itself and the increased risk of death," said Professor Tashkin, principal investigator at the POET-COPD program at the University of California, Los Angeles, at David Geffen School of Medicine. A large study of acute exacerbations of COPD supports tiotropium bromide(136310-93-5) as the preferred maintenance therapy, minimizing the risk of acute exacerbations at the early stage of COPD, enabling patients to live better and longer. "

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved